The Riskalyze Report: US Bonds for sale again

February 9th – 15th 2015

Winners (advisor flows TO these investments increased substantially):  

• Real Estate (VNQ, IYR)
• Apple (AAPL)
• Templeton Global Bond (TPINX)

Losers (advisor flows FROM these investments increased substantially):

• Pfizer (PFE)
• Fixed Income / Bonds (AGG, DFAPX, LDLFX)
• Bristol-Myers Squibb Company (BMY)

Looks like advisors hit the bid on a few popular bond funds last week, possibly on the heels of Friday’s blowout jobs report. On the sell list, Riskalyze saw an intermediate term bond fund from DFA, the iShares proxy for the Barclays Aggregate Bond index and a short-term fund from Lord Abbett that carries paper with an average duration of under two years.

But they were out there buying Templeton’s Global Bond fund, which is heavy on EM nations from Eastern Europe to Asia to LatAM. REIT ETFs caught a bid as well. Looks like a step out onto the risk curve on the fixed income side of some portfolios, perhaps.

We also see some Big Pharma sells in Merck and Pfizer, which are trading at 8- and 11-year highs respectively.

A word about Riskalyze:

In my practice, we use Riskalyze software tools to help assess clients’ true risk tolerance and to test portfolio configurations that match up accordingly. It’s changed our practice for the better, as I explain here.

Check it out today!

*(to state the obvious, Riskalyze does not share client sensitive data with me or use animals in testing).